Pemigatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 4.5 mg, 9 mg, 13.5 mg
Reference Brands: Pemazyre (USA/EU)
Category:
Oncology Cancer Care
Pemigatinib is available in Tablets
and strengths such as 4.5 mg, 9 mg, 13.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pemigatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pemigatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pemigatinib, marketed under the brand name Pemazyre, is an orally bioavailable small-molecule inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1/2/3) with antineoplastic activity. It belongs to the class of protein kinase inhibitors and specifically targets FGFRs, which are receptor tyrosine kinases expressed on the surface of certain cancer cells. These receptors play a critical role in cell proliferation, migration, and survival, and are often upregulated in various tumor types.
By binding to and inhibiting FGFR1/2/3, pemigatinib blocks downstream signal transduction pathways that promote tumor cell growth and proliferation. This mechanism effectively suppresses the growth of FGFR-overexpressing tumor cells and helps prevent cancer progression.
Clinically, pemigatinib is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (bile duct cancer) who harbor FGFR2 fusions or rearrangements and have received prior therapy. Administered orally in tablet form, pemigatinib provides a targeted therapeutic approach, offering a promising option for patients with FGFR-driven cancers. Its selective inhibition of FGFRs contributes to tumor growth control while minimizing effects on non-target cells, making it an important addition to modern oncology care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing